MWNA
CVAC

Marshall Wace North America’s CureVac CVAC Stock Holding History

Marshall Wace North America’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,591
Closed -$2.62M – 1507
2021
Q1 		$2.62M Buy
+28,591
New +$2.77M 0.01% 742
2020
Q4 		– Sell
-35,260
Closed -$1.64M – 1358
2020
Q3 		$1.64M Buy
+35,260
New +$1.97M 0.01% 652

Other funds holding CVAC

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace North America's CVAC Position: Q2 2021 in Review

Marshall Wace North America sold out of CureVac (CVAC) in Q2 2021, closing a stake of 28,591 shares — an estimated $2.62M sold.

Marshall Wace North America first reported a position in CVAC in Q3 2020 and held it in 2 quarters. The position peaked at $2.62M in Q1 2021. 109 funds tracked by Wall St. Rank hold CVAC as of Q2 2021.

  • Marshall Wace North America reported no remaining CureVac position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 28,591 CureVac shares in Q2 2021, an estimated $2.62M.
  • Marshall Wace North America first reported a position in CureVac in Q3 2020 and held it in 2 quarters.
  • Marshall Wace North America's CureVac position peaked at $2.62M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held CureVac as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.